Prosecution Insights
Last updated: April 19, 2026

Novo Nordisk Inc.

28 pending office actions • 2 clients

Portfolio Summary

28
Total Pending OAs
7
Final Rejections
21
Non-Final OAs

Client Portfolio (2 clients)

Client (Assignee)Pending OAs
Novo Nordisk A/S 27
Novo Nordisk Health Care AG 1

Pending Office Actions

App #TitleClientExaminerArt UnitStatusFiled
19422732 Untitled Novo Nordisk A/S HA, JULIE 1654 Non-Final OA
19419518 Untitled Novo Nordisk A/S SHIAO, REI TSANG 1691 Non-Final OA
19310993 SEMAGLUTIDE FOR USE IN MEDICINE Novo Nordisk A/S DABKOWSKI, ERINNE R 1654 Non-Final OA Aug 27, 2025
18874891 SYSTEMS AND METHODS FOR REGIMEN ADHERENCE EVALUATION Novo Nordisk A/S LAGOY, KYRA RAND 3685 Non-Final OA Dec 13, 2024
18578485 SODIUM N-(8-(2- HYDROXYBENZOYL)AMINO)CAPRYLATE POLYMORPHIC FORM A Novo Nordisk A/S MCKOY, QUINCY ANDRE 1626 Non-Final OA Jan 11, 2024
18577720 TABLET COMPRISING A SALT OF N-(8-(2-HYDROXYBENZOYL)AMINO)CAPRYLIC ACID Novo Nordisk A/S CHANG, KYUNG SOOK 1613 Non-Final OA Jan 09, 2024
18576838 METHOD FOR PROVIDING A CELL POPULATION ENRICHED IN NEURONS AND PRECURSORS THEREOF Novo Nordisk A/S MIANO, JOSEPH PAUL 1631 Non-Final OA Jan 05, 2024
18568719 A SINGLE DOSE INJECTION DEVICE Novo Nordisk A/S GILBERT, ANDREW M 3700 Non-Final OA Dec 08, 2023
18289294 INSULIN ON BOARD FOR GLUCOSE SENSITIVE INSULIN Novo Nordisk A/S SHAH, NILAY J 3783 Non-Final OA Nov 02, 2023
18242868 FACTOR X BINDERS ENHANCING FX ACTIVATION Novo Nordisk A/S SZPERKA, MICHAEL EDWARD 1641 Final Rejection Sep 06, 2023
18274614 NOVEL SYNTHESIS OF SALCAPROZIC ACID BY AMIDE FORMATION Novo Nordisk A/S CARR, DEBORAH D 1691 Non-Final OA Jul 27, 2023
18037813 FAST DATA TRANSMISSION FEATURE FOR MEDICAL LOGGING DEVICE Novo Nordisk A/S REGO, DOMINIC E 2648 Non-Final OA May 19, 2023
18026136 PHARMACEUTICAL FORMULATION OF CONCIZUMAB AND METHOD OF PRODUCTION THEREOF Novo Nordisk Health Care AG REDDIG, PETER J 1646 Non-Final OA Mar 14, 2023
18022538 METHOD FOR SCREENING IN VITRO POPULATION OF STEM CELL DERIVED BETA LIKE CELLS AND NOVEL MARKERS THEREOF Novo Nordisk A/S DHAR, MATASHA 1632 Non-Final OA Feb 22, 2023
18017041 CO-AGONISTS AT GLP-1 AND GIP RECEPTORS SUITABLE FOR ORAL DELIVERY Novo Nordisk A/S HA, JULIE 1654 Non-Final OA Jan 19, 2023
18016947 GLP-1 AND GIP RECEPTOR CO-AGONISTS Novo Nordisk A/S CHANDRA, GYAN 1674 Non-Final OA Jan 19, 2023
18015444 METHODS FOR TREATING CARDIOVASCULAR DISEASE Novo Nordisk A/S HOWARD, ZACHARY C 1674 Final Rejection Jan 10, 2023
17913292 Solid Dispersions of Amorphous 3,4-Diphenyl-4,5-Dihydro-1H-Pyrazole Derivatives, Compositions Comprising them and Uses Thereof as Cannabinoid CB1 Receptor Inhibitors Novo Nordisk A/S SAEED, KAMAL A 1626 Non-Final OA Sep 21, 2022
17908750 USE OF PLURIPOTENT MARKERS TO DETECT CONTAMINATING RESIDUAL UNDIFFERENTIATED PLURIPOTENT STEM CELLS Novo Nordisk A/S HANEY, AMANDA MARIE 1682 Non-Final OA Sep 01, 2022
17800747 GLP-1 COMPOSITIONS AND USES THEREOF Novo Nordisk A/S ATKINSON, JOSHUA ALEXANDER 1612 Non-Final OA Aug 18, 2022
17833587 METHODS FOR THE PURIFICATION OF PROTEINS USING CAPRYLIC ACID Novo Nordisk A/S BREEN, KIMBERLY CATHERINE 1657 Non-Final OA Jun 06, 2022
17782249 FIXED DOSE INJECTION DEVICE Novo Nordisk A/S GRASMEDER, SARAH DYMPNA 3783 Final Rejection Jun 03, 2022
17782003 AN INJECTION DEVICE FOR DELIVERING A LIQUID DRUG Novo Nordisk A/S NORTH, ISABELLA SARAH HYO SO 3783 Final Rejection Jun 02, 2022
17616283 APPLICATION OF ANTIARRHYTHMIC AGENTS TO STEM CELL DERIVED CARDIOMYOCYTES AND USES THEREOF Novo Nordisk A/S TRAN, KHOA NHAT 1632 Final Rejection Dec 03, 2021
17512751 Anti-IL-6 Antibody Formulation Novo Nordisk A/S BERHANE, SELAM 1675 Non-Final OA Oct 28, 2021
17598010 GLUCOSE SENSITIVE INSULIN DERIVATIVES Novo Nordisk A/S HA, JULIE 1654 Non-Final OA Sep 24, 2021
17403357 COMPOSITIONS COMPRISING A DELIVERY AGENT AND PREPARATION THEREOF Novo Nordisk A/S REYNOLDS, FRED H 1658 Final Rejection Aug 16, 2021
17270072 SYSTEMS AND METHODS FOR PROVIDING CONTAINER BASED MEDICATION DOSE GUIDANCE TO TREAT DIABETES Novo Nordisk A/S ROSSI, VY BUI 1685 Final Rejection Feb 22, 2021

Managing Novo Nordisk Inc.'s Patent Prosecution?

IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month